ISLAMABAD, July 27 (online): According to a new study, a Chinese phase II clinical trial of a COVID-19 vaccine candidate has shown that it is safe and induces an immune response.
With over 15 million confirmed cases of the new coronavirus, SARS-CoV-2, and more than 624,000 COVID-19 deaths globally, scientists around the world are competing against time to fast-track the development of new treatments to combat the disease.
Globally, scientists are developing about 250 candidate vaccines against SARS-CoV-2 infection. Of these, to date, at least 17 are under evaluation in clinical trials.
The authors of the recent study aimed to evaluate the safety and efficacy of a vaccine candidate called adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine).
They also wanted to determine the most appropriate dose for a phase III trial in the coming months.
Biologics developed the Ad5-vectored COVID-19 vaccine. It uses a weakened human common cold virus (adenovirus) that produces an immune system response, including antibodies, to fight off the coronavirus
“The Beijing approach is based on the backbone of a conventional human, common cold virus to which some people have preexisting antibodies, and they, therefore, make a lower response in some people to the vaccine because people have preexisting antibodies to their vector, so may clear it before it has a chance to work properly.”
Coronavirus kills 20 people with 1,176 new cases reported in last 24 hours
Stay tuned to Baaghi TV for latest news and updates!
